This is a rather special Pharmalittle post, because in actuality Ed Silverman is taking a few days off to be with the Short People, Mrs. Pharmalot, and Pharmalot Mascots. In his place, you get me, Chris Truelove, director of content for UBM Canon Pharma Group, the corporate overlord that owns Pharmalot. It might be a little slow around here, but Ed will be back before you know it (Monday, in fact). In the meantime, I will at least attend to the news links.
But true Ed fashion, he's already pointed out to me a few items of interest that you might like. So here you go. Grab your cup of stimulation (the flavor here right now is plain old Folgers) and take a look:
FDA Bill Up In The Over Proposed Changes (Politico)
J&J's Gorsky Plans A Realistic, But Optimistic Future (Associated Press)
Targacept To Eliminate 65 Jobs (Bloomberg News)
FDA Delays Action On New Takeda Diabetes Drug (Reuters)
FTC Loses Appeal In 'Pay-To-Delay' Court Case (Bloomberg News)
Icahn Drops Lawsuit Against Amylin (Reuters)
Will Congress Pass A 'Track And Trace' Plan? (Chicago Tribune)
Pfizer Drug Reduced Autism Signs In Mice (Bloomberg News)
OIG: Avastin Is A Better Buy For Wet AMD (MedPage Today)






8 Comments
No need to change any habits or inclinations. The song remains the same.
Regards ed
And Ed can't seem to keep away from his e-mail anyway. I have to hop on something he just sent me right now ...
I would seriously know whether this increased interaction was manifested by an increased frequency of squeaking, or did they manage to carry on a serious conversation?